Antibody Genetic Engineering Immune Response Licensing 
The Pharma Data
JANUARY 17, 2021
These models are engrafted with mouse tumors derived from the same strain background; this genetic similarity between tumor and host prevents the host from rejecting the tumor. One consideration in using syngeneic models is that some drug candidates can cause a negative immune response not seen in humans.
The Pharma Data
SEPTEMBER 8, 2020
Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.
The Pharma Data
SEPTEMBER 8, 2020
Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.
Expert insights. Personalized for you.
52 
Let's personalize your content